The moment when treatment becomes most effective is before the cancer spreads
Cancer's greatest cruelty lies not in its origin but in its wandering — the moment cells abandon their home and colonize distant organs. A team of researchers at Queens University Belfast and the University of Southern Denmark has identified 177 genes shared across cancer types that appear to govern this journey, suggesting that what has long been treated as many separate diseases may share a common genetic grammar of spread. The discovery carries both predictive and therapeutic weight: it offers a way to anticipate metastasis before it occurs and points toward an existing drug, Vorinostat, that may help stop it.
- Metastasis — not the original tumor — is responsible for the vast majority of cancer deaths, making its prediction and prevention one of medicine's most urgent unsolved problems.
- For decades, the assumption that each cancer type spreads through its own unique mechanisms has fragmented research and limited the reach of any single therapeutic breakthrough.
- The identification of a 177-gene 'pan-cancer' signature, including the accelerant SP1 and the suppressor KLF5, directly challenges that fragmentation and opens a unified front against spread.
- Because Vorinostat is already FDA-approved, the path from laboratory finding to patient treatment could be compressed dramatically — bypassing the years-long gauntlet of new drug development.
- The research is now pointing toward a future where cancer is classified less by the organ it occupies and more by the genetic behavior driving it, a reorientation that could extend survival for millions.
Cancer kills most of its victims not at first diagnosis, but when it spreads. Metastasis — the escape of tumor cells into distant organs — accounts for the overwhelming majority of cancer deaths, yet for decades researchers approached each cancer type as its own separate puzzle. A team led by Ryan Lusby at Queens University Belfast and Vijay Tiwari at the University of Southern Denmark has now challenged that assumption: by analyzing genetic data across multiple cancers, they identified 177 genes that consistently appear active in tumors that are spreading or poised to spread.
This 'pan-cancer' signature suggests that despite their surface differences, many cancers share a common genetic architecture of metastasis. Two genes stand out within the 177: SP1, which accelerates spread, and KLF5, which suppresses it. The mechanism involves intensifying molecular communication between tumor cells and their surrounding environment through a signaling pathway called WNT — a conversation that, once understood, can potentially be interrupted.
The practical implications arrive on two fronts. First, the signature offers predictive power: examining these genes in a patient's tumor could reveal metastatic risk before spread actually occurs, opening a critical window for early intervention. Second, the researchers identified Vorinostat — an already FDA-approved drug — as a candidate for blocking the process, meaning the timeline between discovery and patient access could be compressed significantly.
For patients and families, this research gestures toward a meaningful shift: a future in which cancer is treated according to the genetic vulnerabilities driving its behavior rather than the organ where it began — a framework that could extend survival and ease the compounding burden that advanced cancer imposes on those it touches.
Cancer kills most of its victims not when it first appears, but when it spreads. Metastasis—the process by which cancer cells escape a tumor and establish themselves in distant organs—accounts for the vast majority of cancer deaths. For decades, researchers treated each cancer type as its own puzzle, assuming the mechanisms that drive spread were fundamentally different between lung cancer and liver cancer, between breast cancer and pancreatic cancer. A team of scientists has now challenged that assumption with a finding that could reshape how oncologists think about treatment: they have identified 177 genes that appear to drive metastasis across multiple cancer types, suggesting that despite their surface differences, cancers may spread through shared genetic pathways.
The discovery emerged from work led by Ryan Lusby at Queens University Belfast and Vijay Tiwari at the University of Southern Denmark. By analyzing genetic data across different cancers, the researchers identified what they call a "pan-cancer" signature—a set of genes that consistently appear active in tumors that are spreading or likely to spread. Among these 177 genes, two stand out: SP1, which accelerates the metastatic process, and KLF5, which suppresses it. The finding is significant because it suggests that a single therapeutic approach might work across cancers that have historically been treated as entirely separate diseases.
What makes this discovery immediately practical is its predictive power. By examining the 177-gene signature in a patient's tumor, doctors could potentially determine whether that cancer is likely to metastasize before it actually does. This window of opportunity—the period between diagnosis and spread—is where intervention becomes most effective. Tiwari explains the stakes plainly: patients whose cancers are caught before metastasis occurs could benefit from early treatment to block the spread process before it becomes life-threatening. The research also identified an existing drug, Vorinostat, which is already FDA-approved for other conditions, as a candidate for blocking metastasis. Rather than waiting years for entirely new medications to be developed and approved, doctors could potentially repurpose drugs already on the market, compressing the timeline between discovery and patient access.
The genetic mechanism underlying metastasis involves what researchers describe as increasingly dynamic communication between tumor cells and their surrounding microenvironment. As metastasis progresses, this conversation intensifies through a signaling pathway called WNT, which is driven by the transcription factor SP1. Understanding this conversation at the molecular level opens the door to interrupting it—to essentially silencing the signals that tell cancer cells to leave the primary tumor and establish themselves elsewhere.
For patients and families, the implications are substantial. Cancer metastasis represents a threshold moment in the disease trajectory, the point at which treatment becomes exponentially harder and outcomes grow grimmer. A genetic framework that allows earlier detection of metastatic risk, combined with the ability to repurpose existing drugs rather than waiting for new ones, could extend survival and reduce the cumulative burden—emotional, physical, and financial—that advanced cancer imposes. The research suggests a future in which cancer treatment becomes less about the organ where the cancer originated and more about the genetic vulnerabilities that drive its behavior, a shift that could benefit far more patients than approaches tailored to individual cancer types.
Citações Notáveis
By understanding and targeting the genetic triggers behind metastasis, this research offers a lifeline: longer, healthier lives and a reduction in the emotional and financial burdens of advanced cancer.— Research team findings
Repurposing approved drugs could make these treatments available to patients much sooner than if entirely new medications were developed.— Vijay Tiwari, University of Southern Denmark
A Conversa do Hearth Outra perspectiva sobre a história
So these 177 genes appear in different cancers—lung, liver, others. Does that mean lung cancer and liver cancer are actually the same disease?
No, they're still distinct diseases in how they start and where they grow. But the research suggests that once a cancer decides to spread, it uses similar genetic machinery regardless of its origin. It's like different cars using the same highway system.
And SP1 and KLF5—one accelerates, one brakes. Is the goal to shut down SP1 or boost KLF5?
Both could work in theory. But the immediate opportunity is targeting SP1, because they've already found an existing drug—Vorinostat—that might do that. Boosting KLF5 would require developing something new, which takes years.
Why does it matter that they can predict metastasis risk before it happens?
Because metastasis is when cancer becomes nearly impossible to cure. If you can identify which patients will metastasize and treat them before it occurs, you're intervening at the moment when treatment is most likely to work. It's the difference between stopping a fire in one room versus fighting it across an entire building.
The drug repurposing angle—is that just about speed, or is there something else?
It's primarily about speed and access. Vorinostat is already approved, so doctors could start using it for metastasis prevention much sooner than waiting for a new drug to go through trials. But it also means the treatment might be more affordable, since the drug is already manufactured and distributed.
Does this change how doctors will actually treat cancer patients soon, or is this still years away?
The genetic signature itself could be used now—hospitals could start testing tumors for this 177-gene pattern to assess metastatic risk. The drug repurposing is closer than most breakthroughs, but it would still need clinical trials to confirm it works. So you're looking at a mix of immediate applications and near-term ones.